In the past week, ESPR stock has gone down by -6.54%, with a monthly gain of 17.67% and a quarterly plunge of -30.56%. The volatility ratio for the week is 6.65%, and the volatility levels for the last 30 days are 7.50% for Esperion Therapeutics Inc The simple moving average for the last 20 days is -9.49% for ESPR stock, with a simple moving average of -42.06% for the last 200 days.
Is It Worth Investing in Esperion Therapeutics Inc (NASDAQ: ESPR) Right Now?
Additionally, the 36-month beta value for ESPR is 0.70. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for ESPR is 194.62M and currently, short sellers hold a 12.39% ratio of that float. The average trading volume of ESPR on July 02, 2025 was 5.16M shares.
ESPR) stock’s latest price update
The stock of Esperion Therapeutics Inc (NASDAQ: ESPR) has increased by 1.58 when compared to last closing price of 0.98. Despite this, the company has experienced a -6.54% fall in its stock price over the last five trading sessions. globenewswire.com reported 2025-07-01 that Brings More Than Twenty Years of Biopharmaceutical Leadership Experience Brings More Than Twenty Years of Biopharmaceutical Leadership Experience
Analysts’ Opinion of ESPR
Many brokerage firms have already submitted their reports for ESPR stocks, with Goldman repeating the rating for ESPR by listing it as a “Neutral.” The predicted price for ESPR in the upcoming period, according to Goldman is $4 based on the research report published on December 18, 2024 of the previous year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see ESPR reach a price target of $8. The rating they have provided for ESPR stocks is “Overweight” according to the report published on December 17th, 2024.
BofA Securities gave a rating of “Underperform” to ESPR, setting the target price at $2.50 in the report published on June 20th of the previous year.
ESPR Trading at 2.97% from the 50-Day Moving Average
After a stumble in the market that brought ESPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.62% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ESPR starting from Looker Benjamin, who sale 6,422 shares at the price of $1.15 back on Jun 17 ’25. After this action, Looker Benjamin now owns 401,241 shares of Esperion Therapeutics Inc, valued at $7,398 using the latest closing price.
Koenig Sheldon L., the President and CEO of Esperion Therapeutics Inc, sale 30,474 shares at $1.11 during a trade that took place back on Jun 17 ’25, which means that Koenig Sheldon L. is holding 1,541,488 shares at $33,796 based on the most recent closing price.
Stock Fundamentals for ESPR
Current profitability levels for the company are sitting at:
- -0.15 for the present operating margin
- 0.65 for the gross margin
The net margin for Esperion Therapeutics Inc stands at -0.59. The total capital return value is set at -0.75.
Based on Esperion Therapeutics Inc (ESPR), the company’s capital structure generated -2.32 points at debt to capital in total, while cash flow to debt ratio is standing at -0.34. The debt to equity ratio resting at -0.7. The interest coverage ratio of the stock is -0.62.
Currently, EBITDA for the company is 7.57 million with net debt to EBITDA at -2.07. When we switch over and look at the enterprise to sales, we see a ratio of 1.47. The receivables turnover for the company is 3.19for trailing twelve months and the total asset turnover is 0.8. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.18.
Conclusion
In conclusion, Esperion Therapeutics Inc (ESPR) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
